CRISPR-Gold Fixes Duchenne Muscular Dystrophy Mutation in Mice – Bioscience Technology
|
CRISPR-Gold Fixes Duchenne Muscular Dystrophy Mutation in Mice
Bioscience Technology CRISPR–Gold is composed of 15 nanometer gold nanoparticles that are conjugated to thiol-modified oligonucleotides (DNA-Thiol), which are hybridized with single-stranded donor DNA and subsequently complexed with Cas9 and encapsulated by a polymer … |
|
Celsion’s Immunotherapy Candidate Impresses, Stock Surges
Nasdaq Celsion CorporationCLSN announced results from phase Ib study – OVATION – evidently showing biological activity of its immunotherapy candidate, GEN1, in advanced ovarian cancer patients. Celsion is developing the candidate for newly diagnosed … |
KQED |
Spinal Patients Continue Remarkable Recovery After Stem Cell Injections, Company Says
KQED Patients with spinal injuries have continued to heal long after they’ve received an initial injection of stem cells, according to data released Oct. 2 by the biotech company conducting a clinical trial on the treatment. ‘The rate of recovery at 12 … |
Labiotech.eu (blog) |
Celyad: First “Clinical Validity” For NKR CAR T-Cells
Investing.com Celyad SA (NASDAQ:CYAD) has reported a complete morphological leukaemia-free status (MFLS) response in acute myeloid leukaemia (AML) in the NKR CAR T-cell THINK study. Given that spontaneous remission in refractory/relapsed AML is extremely … Belgian Biotech’s Leukemia CAR–T Treatment Leaves Patient Cancer-FreeLabiotech.eu (blog) |